• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Epidemiology and Genetics >Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study
【24h】

Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study

机译：他莫昔芬代谢基因的变体：WECARE研究中对侧乳腺癌风险的病例对照研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tamoxifen has been shown to greatly reduce risk of recurrence and contralateral breast cancer (CBC). Still, second primary contralateral breast cancer is the most common malignancy to follow a first primary breast cancer. Genetic variants in emCYP2D6/em and other drug-metabolizing enzymes that alter the metabolism of tamoxifen may be associated with CBC risk in women who receive the drug. This is the first study to investigate the impact of this variation on risk of CBC in women who receive tamoxifen. From the population-based Women’s Environment Cancer and Radiation Epidemiology (WECARE) Study, we included 624 Caucasian women with CBC (cases) and 1,199 women with unilateral breast cancer (controls) with complete information on tumor characteristics and treatment. Conditional logistic regression was used to assess the risk of CBC associated with 112 single nucleotide polymorphisms (SNPs) in 8 genes involved in the metabolism of tamoxifen among tamoxifen users and non-users. After adjustment for multiple testing, no significant association was observed between any of the genotyped variants and CBC risk in either tamoxifen users or non-users. These results suggest that when using a tagSNP approach, common variants in selected genes involved in the metabolism of tamoxifen are not associated with risk of CBC among women treated with the drug.
机译：他莫昔芬已被证明可以大大降低复发和对侧乳腺癌（CBC）的风险。但是，第二原发对侧乳腺癌是继第一原发乳腺癌之后最常见的恶性肿瘤。 CYP2D6 和其他药物代谢酶中的遗传变异会改变他莫昔芬的代谢，可能与接受该药物的女性的CBC风险有关。这是第一项研究这种变化对接受他莫昔芬治疗的女性的CBC风险影响的研究。从基于人群的妇女环境癌症和放射流行病学（WECARE）研究中，我们纳入了624名患有CBC的白人妇女（病例）和1,199名患有单侧乳腺癌的妇女（对照），并提供了有关肿瘤特征和治疗的完整信息。使用条件逻辑回归分析评估了他莫昔芬使用者和非使用者中与他莫昔芬代谢有关的8个基因中与112个单核苷酸多态性（SNP）相关的CBC风险。经过多次测试调整后，他莫昔芬使用者或非使用者中任何基因型变异与CBC风险之间均未发现显着相关性。这些结果表明，当使用tagSNP方法时，参与他莫昔芬代谢的选定基因的常见变异与接受该药物治疗的女性的CBC风险无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号